Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ESR1 | P03372 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | ELANE | P08246 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28493468 | 0.87 | BCL9 (0.53) | KMT2ASMN1; SMN2ESR1HIF1ARECQL | |
| SCHEMBL15708320 | 0.86 | KMT2A (0.53) | KMT2ASMN1; SMN2ESR1HIF1ARECQL | |
| SCHEMBL2577691 | 0.83 | CYP3A4 (0.44) | KMT2ASMN1; SMN2ESR1HIF1ARECQL | |
| SCHEMBL16270524 | 0.81 | GAA (0.51) | KMT2ASMN1; SMN2CYP3A4TSHRMAPT | |
| SCHEMBL312147 | 0.81 | KMT2A (0.76) | KMT2ASMN1; SMN2ESR1HIF1ARECQL | |
| SCHEMBL3420578 | 0.80 | LMNA (0.53) | KMT2ASMN1; SMN2ESR1ELANECYP3A4 | |
| SCHEMBL15708348 | 0.80 | CYP3A4 (0.42) | KMT2ASMN1; SMN2ESR1HIF1ARECQL | |
| SCHEMBL11445596 | 0.79 | KMT2A (0.73) | KMT2ASMN1; SMN2ESR1HIF1ARECQL | |
| SCHEMBL10392664 | 0.79 | KMT2A (0.42) | KMT2ASMN1; SMN2ESR1HIF1ARECQL | |
| SCHEMBL15708839 | 0.79 | KMT2A (0.42) | KMT2ASMN1; SMN2ESR1HIF1ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113371-A9 | Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds | RANBAXY LABORATORIES LIMITED INC. (IN) | 2010-05-06 | — | — | US | disclosed |
| US-20090075909-A1 | Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds | RANBAXY LABORATORIES LIMITED INC. (IN) | 2009-03-19 | — | — | US | disclosed |
| US-20090048186-A1 | Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-19 | — | — | US | disclosed |
| US-20080114031-A1 | MONOSACCHARIDE DERIVATIVES | RANBAXY LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | disclosed |
| EP-1902063-A2 | DERIVATIVES OF PENTOSE MONOSACCHARIDES AS ANTI-INFLAMMATORY COMPOUNDS | Ranbaxy Laboratories Limited (IN) | 2008-03-26 | — | — | EP | disclosed |
| EP-1874788-A1 | MONOSACCHARIDE DERIVATIVES AS ANTI-INFLAMMATORY AND/OR ANTI-CANCER AGENTS | Ranbaxy Laboratories Limited (IN) | 2008-01-09 | — | — | EP | disclosed |
| EP-1842855-A2 | MONOSACCHARIDE DERIVATIVES AS ANTI-INFLAMMATORY AND/OR ANTI-CANCER AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-10-10 | — | — | EP | disclosed |
| WO-2007063356-A2 | DERIVATIVES OF PENTOSE MONOSACCHARIDES AS ANTI-INFLAMMATORY COMPOUNDS | RANBAXY LABORATORIES LIMITED (IN) | 2007-06-07 | — | — | WO | disclosed |
| WO-2006111783-A1 | MONOSACCHARIDE DERIVATIVES AS ANTI-INFLAMMATORY AND/OR ANTI-CANCER AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-10-26 | — | — | WO | disclosed |
| WO-2005100373-A2 | MONOSACCHARIDE DERIVATIVES AS ANTI-CANCER AND ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048186-A1 | Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents | HLA-DRB1, MUC1, ASGR1 | KMT2A 4199/4885SMN1; SMN2 4758/4885ESR1 983/4885 |
| US-20090075909-A1 | Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds | HLA-DRB1, IL5, TNF | KMT2A 4338/4885SMN1; SMN2 4524/4885ESR1 4093/4885 |
| US-20080114031-A1 | MONOSACCHARIDE DERIVATIVES | HLA-DRB1, MUC1, FUT5 | KMT2A 4114/4885SMN1; SMN2 4734/4885ESR1 1001/4885 |
| US-20100113371-A9 | Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds | HLA-DRB1, IL5, TNF | KMT2A 4338/4885SMN1; SMN2 4524/4885ESR1 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.